Guardant Health/$GH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
$GH
Sector
Primary listing
Employees
2,010
Headquarters
Website
Guardant Health Metrics
BasicAdvanced
$8.2B
-
-$3.35
1.45
-
Price and volume
Market cap
$8.2B
Beta
1.45
52-week high
$68.23
52-week low
$20.14
Average daily volume
2.2M
Financial strength
Current ratio
3.705
Quick ratio
2.739
Long term debt to equity
-428.144
Total debt to equity
-436.746
Interest coverage (TTM)
-150.23%
Profitability
EBITDA (TTM)
-419.117
Gross margin (TTM)
62.84%
Net profit margin (TTM)
-49.93%
Operating margin (TTM)
-55.55%
Effective tax rate (TTM)
-0.26%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-19.57%
Return on equity (TTM)
269.51%
Valuation
Price to revenue (TTM)
9.77
Price to book
-26.67
Price to tangible book (TTM)
-25.9
Price to free cash flow (TTM)
-29.8
Free cash flow yield (TTM)
-3.36%
Free cash flow per share (TTM)
-2.197
Growth
Revenue change (TTM)
28.74%
Earnings per share change (TTM)
-18.10%
3-year revenue growth (CAGR)
26.64%
3-year earnings per share growth (CAGR)
-14.84%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Bulls say / Bears say
Guardant delivered $232.1 million in Q2 2025 revenue, up 31% year-over-year, and raised full-year guidance to $915–$925 million, reflecting strong commercial momentum (Business Wire)
Non-GAAP gross margin expanded to 66% in Q2 2025, up from 60% a year earlier, demonstrating improved unit economics across oncology and screening assays (Business Wire)
Shield’s multi-cancer detection (MCD) test received FDA Breakthrough Device designation, secured NCCN guideline inclusion for colorectal screening, and began patient enrollment in the NCI Vanguard study, underscoring strong regulatory and clinical validation (Business Wire)
Despite a 31% revenue increase, Guardant reported a net loss of $99.9 million in Q2 2025, highlighting ongoing unprofitability as it scales its business (Business Wire)
Operating expenses surged to $257.3 million in Q2 2025, a 25% year-over-year increase driven by commercialization efforts for Shield and new product launches, pressuring margins (Business Wire)
Guardant expects full-year 2025 free cash flow burn of $225–235 million, including approximately $200 million of screening net cash burn, which may strain its cash runway if adoption lags forecasts (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Guardant Health News
AllArticlesVideos
S&P 500's New AI Play? Walmart In Buy Zone, Leads Five Stocks To Watch Amid Volatile Market
Investors Business Daily1 day ago
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
Business Wire4 days ago
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Guardant Health stock?
Guardant Health (GH) has a market cap of $8.2B as of October 19, 2025.
What is the P/E ratio for Guardant Health stock?
The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of October 19, 2025.
Does Guardant Health stock pay dividends?
No, Guardant Health (GH) stock does not pay dividends to its shareholders as of October 19, 2025.
When is the next Guardant Health dividend payment date?
Guardant Health (GH) stock does not pay dividends to its shareholders.
What is the beta indicator for Guardant Health?
Guardant Health (GH) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.